BioStock: Biosergen advances antifungal drug with strong Q1 results
Biosergen’s Q1 report highlights the successful completion of the second patient cohort in its BSG005 proof-of-concept clinical trial, targeting life-threatening fungal infections. CEO Tine Olesen describes the results as demonstrating real therapeutic potential, paving the way for the third cohort in Q4 2025. We reached out to Olesen for a comment.
Read the interview at biostock.se:
https://biostock.se/en/2025/05/biosergen-advances-antifungal-drug-with-strong-q1-results/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/